UK markets closed

Cyclo Therapeutics, Inc. (CYTH)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.70-0.08 (-1.18%)
At close: 4:00PM EDT
6.64 -0.06 (-0.90%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.78
Open6.66
Bid6.66 x 900
Ask6.70 x 900
Day's range6.55 - 6.70
52-week range3.00 - 17.75
Volume28,643
Avg. volume50,496
Market cap43.136M
Beta (5Y monthly)-0.89
PE ratio (TTM)N/A
EPS (TTM)-3.03
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.00
  • Business Wire

    Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab

    GAINESVILLE, Fla., October 06, 2021--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will participate in the 2021 Virtual Cyclodextrin Conference hosted by CycloLab, "Cyclodextrins as active ingredients in the 21st century," taking place on October 11, 2021.

  • Business Wire

    Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer

    GAINESVILLE, Fla., September 27, 2021--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Lise Lund Kjems, MD, PhD as Chief Medical Officer. Gerald F. Cox, MD, PhD, who has served as the Company’s Acting Chief Medical Officer in a consultant role since March 2021, has

  • Business Wire

    Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

    GAINESVILLE, Fla., September 15, 2021--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Sharon Hrynkow, PhD, Chief Scientific Officer and Senior Vice President for Medical Affairs of Cyclo Therapeutics, will present at the virtual Oppenhe